Effect of neoadjuvant chemotherapy in combined with laparoscopy on the molecular markers and immune function in patients with locally advanced cervical cancer

Objective: To explore the efficacy of paclitaxel plus cisplatin (TP) neoadjuvant chemotherapy in combined with laparoscopy in the treatment of locally advanced cervical cancer and their effect on the molecular markers and immune function. Methods: A total of 92 patients with locally advanced cerv...

Full description

Bibliographic Details
Main Authors: Yu-Na Liu, Peng He, Wen-Hong Han, Li Chen
Format: Article
Language:English
Published: Editorial Board of Journal of Hainan Medical University 2017-10-01
Series:Journal of Hainan Medical University
Subjects:
Online Access:http://www.hnykdxxb.com/PDF/201719/35.pdf
id doaj-26f6dc35177a4d1c90a583842f5c49b4
record_format Article
spelling doaj-26f6dc35177a4d1c90a583842f5c49b42020-11-25T00:40:05ZengEditorial Board of Journal of Hainan Medical UniversityJournal of Hainan Medical University1007-12371007-12372017-10-012319142145Effect of neoadjuvant chemotherapy in combined with laparoscopy on the molecular markers and immune function in patients with locally advanced cervical cancerYu-Na Liu0Peng He1Wen-Hong Han2Li Chen3The First Central Hospital of Baoding City, Hebei, 071028The 252th Hospital of Chinese People ’ s Liberation Army, 071000The First Central Hospital of Baoding City, Hebei, 071028The First Central Hospital of Baoding City, Hebei, 071028Objective: To explore the efficacy of paclitaxel plus cisplatin (TP) neoadjuvant chemotherapy in combined with laparoscopy in the treatment of locally advanced cervical cancer and their effect on the molecular markers and immune function. Methods: A total of 92 patients with locally advanced cervical cancer were included in the study and divided into the control group (n=46) and the treatment group (n=46) according to the admission number. The patients in the control group were given 5- fluorouracil plus cisplatin (PF), neoadjuvant chemotherapy in combined with laparoscopic radical hysterectomy. The patients in the treatment group were given TP neoadjuvant chemotherapy in combined with laparoscopic radical hysterectomy. The clinical efficacy in the two groups was compared. The levels of molecular markers and the change of immune function in the two groups were detected and compared. The adverse reactions in the two groups were observed and compared. Results: After chemotherapy, in the treatment group, CR was 39.13%, PR was 41.30%, NC was 13.04%, PD was 6.52%, and the total effective rate was 80.43%, while those in the control group were 21.74%, 26.09%, 30.43%, 21.74%, and 47.83%, respectively. The total effective rate in the treatment group was significantly higher than that in the control group. The comparison of the occurrence rate of adverse reactions between the two groups was not statistically significant. CEA, SCC-Ag, CYFRA21-1, and CA125 levels 2 weeks after operation in the two groups were significantly reduced when compared with before treatment, and those in the treatment group were significantly lower than those in the control group. MMP-2, TIMP-2, VEGF-C, and VEGF-D levels 2 weeks after operation in the two groups were significantly reduced when compared with before treatment, and those in the treatment group were significantly lower than those in the control group. CD 3 + , CD 4 + , and CD 8 + 2 weeks after operation in the two groups were significantly reduced when compared with before treatment, while CD 4 + /CD 8 + was significantly elevated, but the comparison between the two groups was not statistically significant. Conclusions: Given TP neoadjuvant chemotherapy in combined with laparoscopy in patients with locally advanced cervical cancer can obviously enhance the patient's clinical efficacy, reduce the molecular markers in the body, effectively improve the patient's immune functionwith less adverse reactions and accurate efficacy; therefore, they are safe and reliable.http://www.hnykdxxb.com/PDF/201719/35.pdfNeoadjuvant chemotherapyLaparoscopyCervical cancerMolecular markersImmune function
collection DOAJ
language English
format Article
sources DOAJ
author Yu-Na Liu
Peng He
Wen-Hong Han
Li Chen
spellingShingle Yu-Na Liu
Peng He
Wen-Hong Han
Li Chen
Effect of neoadjuvant chemotherapy in combined with laparoscopy on the molecular markers and immune function in patients with locally advanced cervical cancer
Journal of Hainan Medical University
Neoadjuvant chemotherapy
Laparoscopy
Cervical cancer
Molecular markers
Immune function
author_facet Yu-Na Liu
Peng He
Wen-Hong Han
Li Chen
author_sort Yu-Na Liu
title Effect of neoadjuvant chemotherapy in combined with laparoscopy on the molecular markers and immune function in patients with locally advanced cervical cancer
title_short Effect of neoadjuvant chemotherapy in combined with laparoscopy on the molecular markers and immune function in patients with locally advanced cervical cancer
title_full Effect of neoadjuvant chemotherapy in combined with laparoscopy on the molecular markers and immune function in patients with locally advanced cervical cancer
title_fullStr Effect of neoadjuvant chemotherapy in combined with laparoscopy on the molecular markers and immune function in patients with locally advanced cervical cancer
title_full_unstemmed Effect of neoadjuvant chemotherapy in combined with laparoscopy on the molecular markers and immune function in patients with locally advanced cervical cancer
title_sort effect of neoadjuvant chemotherapy in combined with laparoscopy on the molecular markers and immune function in patients with locally advanced cervical cancer
publisher Editorial Board of Journal of Hainan Medical University
series Journal of Hainan Medical University
issn 1007-1237
1007-1237
publishDate 2017-10-01
description Objective: To explore the efficacy of paclitaxel plus cisplatin (TP) neoadjuvant chemotherapy in combined with laparoscopy in the treatment of locally advanced cervical cancer and their effect on the molecular markers and immune function. Methods: A total of 92 patients with locally advanced cervical cancer were included in the study and divided into the control group (n=46) and the treatment group (n=46) according to the admission number. The patients in the control group were given 5- fluorouracil plus cisplatin (PF), neoadjuvant chemotherapy in combined with laparoscopic radical hysterectomy. The patients in the treatment group were given TP neoadjuvant chemotherapy in combined with laparoscopic radical hysterectomy. The clinical efficacy in the two groups was compared. The levels of molecular markers and the change of immune function in the two groups were detected and compared. The adverse reactions in the two groups were observed and compared. Results: After chemotherapy, in the treatment group, CR was 39.13%, PR was 41.30%, NC was 13.04%, PD was 6.52%, and the total effective rate was 80.43%, while those in the control group were 21.74%, 26.09%, 30.43%, 21.74%, and 47.83%, respectively. The total effective rate in the treatment group was significantly higher than that in the control group. The comparison of the occurrence rate of adverse reactions between the two groups was not statistically significant. CEA, SCC-Ag, CYFRA21-1, and CA125 levels 2 weeks after operation in the two groups were significantly reduced when compared with before treatment, and those in the treatment group were significantly lower than those in the control group. MMP-2, TIMP-2, VEGF-C, and VEGF-D levels 2 weeks after operation in the two groups were significantly reduced when compared with before treatment, and those in the treatment group were significantly lower than those in the control group. CD 3 + , CD 4 + , and CD 8 + 2 weeks after operation in the two groups were significantly reduced when compared with before treatment, while CD 4 + /CD 8 + was significantly elevated, but the comparison between the two groups was not statistically significant. Conclusions: Given TP neoadjuvant chemotherapy in combined with laparoscopy in patients with locally advanced cervical cancer can obviously enhance the patient's clinical efficacy, reduce the molecular markers in the body, effectively improve the patient's immune functionwith less adverse reactions and accurate efficacy; therefore, they are safe and reliable.
topic Neoadjuvant chemotherapy
Laparoscopy
Cervical cancer
Molecular markers
Immune function
url http://www.hnykdxxb.com/PDF/201719/35.pdf
work_keys_str_mv AT yunaliu effectofneoadjuvantchemotherapyincombinedwithlaparoscopyonthemolecularmarkersandimmunefunctioninpatientswithlocallyadvancedcervicalcancer
AT penghe effectofneoadjuvantchemotherapyincombinedwithlaparoscopyonthemolecularmarkersandimmunefunctioninpatientswithlocallyadvancedcervicalcancer
AT wenhonghan effectofneoadjuvantchemotherapyincombinedwithlaparoscopyonthemolecularmarkersandimmunefunctioninpatientswithlocallyadvancedcervicalcancer
AT lichen effectofneoadjuvantchemotherapyincombinedwithlaparoscopyonthemolecularmarkersandimmunefunctioninpatientswithlocallyadvancedcervicalcancer
_version_ 1725291552054444032